Retractable Technologies patent victory
This article was originally published in The Gray Sheet
Executive Summary
Little Elm, Texas, firm is awarded damages of $5 million in patent infringement suit against Becton Dickinson, the firm announces Nov. 10. BD's Integra syringes infringe three valid patents held by Retractable Technologies, the Eastern District of Texas jury found. Retractable's VanishPoint automated retraction safety syringes and blood collection devices feature a patented friction ring mechanism that causes contaminated needles to retract automatically to prevent accidental needle stick injuries and device reuse. In 2004, BD settled with a $100 million pay-out charges that it had conspired with group purchasing organizations and other manufacturers to prevent VanishPoint sales (1"The Gray Sheet" July 5, 2004)
You may also be interested in...
BD/RTI syringe settlement
Retractable Technologies, Inc. will receive $100 mil. from BD to settle a 1999 lawsuit alleging conspiracy to prevent sales of its VanishPoint retractable syringes. RTI settled with the three other defendants - competitor Tyco Healthcare and hospital group purchasing organizations Premier and Novation - in May 2003, providing access to contracts and financial remuneration (1"The Gray Sheet" March 1, 1999, p. 20)...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.